Primary Efficacy Measures

• Pre-dose FEV1

  • FP vs. Placebo
  • FSC vs. SAL (contribution of FP)

• 2 hour post-dose FEV1

  • FSC vs. FP (contribution of SAL)

Previous slide

Next slide

Back to first slide

View graphic version